

REMARKS

Claims 41, 45, 53-54, 62, 64, 72-73 and 88-89 were allowed in the Notice of Allowance mailed on May 11, 2004. Originally numbered claims 1-40, 42-44, 46-52, 55-61, 63, 65-71, 74-87 and 90-101 were canceled previously.

Pursuant to the undersigned's telephone conference with Examiner Mertz on July 12, 2004, Applicants elect to amend claims 41, 53 and 88 and to cancel claims 45, 54 and 89 without prejudice to the inclusion of these claims in any later filed divisional or continuation application. Applicants further wish to cancel claims 62, 64, 72 and 73 without prejudice to the inclusion of these claims in any later filed divisional or continuation application. A listing of the claims allowed in the Notice of Allowance, now amended, has been set forth below in order to indicate the status of the claims upon entry of this Amendment.

The amendments to claims 53 and 88 merely incorporate the subject matter of dependent claims into independent claims and therefore add no new matter.

Claim 41. (Currently Amended) A method of treating an allergy in a mammal, said method comprising administering to said mammal an anti-histamine antibody and interferon gamma, thereby treating an allergy in a mammal.

Claim 45. (Allowed) The method of claim 41, said method further comprising administering interferon gamma to said mammal.

Claim 53. (Currently Amended) A kit for treating an allergy in a mammal, said kit comprising an anti-histamine antibody, interferon gamma, an applicator, and an instructional material for the use thereof.

Claim 54. (Canceled)

Claim 62. (Canceled)

Claim 64. (Canceled)

Claim 72. (Canceled)

Claim 73. (Canceled)

Claim 88. (Currently Amended) A pharmaceutical composition comprising a protein in an amount effective for treating an allergy in a mammal, wherein said protein is an anti-histamine antibody in a pharmaceutically acceptable carrier, said pharmaceutical composition further comprising interferon gamma.

Claim 89. (Canceled)

Summary

Applicants respectfully submit that the present Amendment is being filed before payment of the issue fee pursuant to 37 C.F.R. §1.312, and respectfully request entry of the present Amendment into the record. Applicants further submit that the present Amendment adds no new matter.

Respectfully submitted,

Boris Skurkovich et al.

By:



July 12, 2004
(Date)

JUSTIN D.G. BRENNAN
Registration No. 52,650
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-5002
Facsimile: (215) 963-5001
E-Mail: jbrennan@morganlewis.com
Agent for Applicants

JDGB